Rehnqvist 1984.

Study characteristics
Methods	Parallel design (2 arms) Country: Sweden Follow‐up period: 24 hours
Participants	Randomly assigned: N = 20 Lidocaine group: 50% (10/20) Propofenone group: 50% (10/20) Age, years: 61 (both groups) Gender, male, % (n/N) Propafenone: 60 (6/10) Lidocaine: not reported Inclusion criteria High‐grade premature ventricular complexes when monitored routinely within 24 hours of admission < 75 years of age Chest pain suggesting an acute myocardial infarction Exclusion criteria Hypersensitivity to procaine or amide types of drugs or local anaesthetic drugs Severe congestive heart failure Atriovenricular block II and III Complete bundle branch blocks Bradycardia (< 50 beats/min) Treatment with other antiarrhythmic drugs, except β‐blocking agents or digitalis, long QT interval
Interventions	Lidocaine Bolus injection of 75 mg Followed by continuous infusion at a rate of 2 mg/min, which could be increased to 3 mg/min Propafenone Bolus injection of 1 mg/kg up to 70 mg Followed by 150 mg orally after 1 hour Co‐interventions: not reported
Outcomes	Reduction in premature ventricular complexes
Notes	A priori sample size estimation: not reported Sponsor: not reported. Trial conduction dates: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"The patients were randomly allocated..." (page 527) Insufficient information about the sequence generation process to permit judgement of ‘low risk’ or ‘high risk’
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement of ‘low risk’ or ‘high risk’
Blinding of participants and personnel (performance bias) All outcomes	High risk	"... in an open fashion" (page 22)
Blinding of outcome assessment (detection bias) All outcomes	High risk	"... in an open fashion" (page 22)
Incomplete outcome data (attrition bias) All outcomes	High risk	Withdrawal from study Propafenone group: 30% (3/10) Lidocaine group: not reported Reason Increasing numbers of premature ventricular complexes
Selective reporting (reporting bias)	High risk	"The study report fails to include results for a key outcome that would be expected to have been reported such a study" This study did not report mortality
Other bias	High risk	Bias of presentation data, design bias (Porta 2008)